<code id='4BC1677A44'></code><style id='4BC1677A44'></style>
    • <acronym id='4BC1677A44'></acronym>
      <center id='4BC1677A44'><center id='4BC1677A44'><tfoot id='4BC1677A44'></tfoot></center><abbr id='4BC1677A44'><dir id='4BC1677A44'><tfoot id='4BC1677A44'></tfoot><noframes id='4BC1677A44'>

    • <optgroup id='4BC1677A44'><strike id='4BC1677A44'><sup id='4BC1677A44'></sup></strike><code id='4BC1677A44'></code></optgroup>
        1. <b id='4BC1677A44'><label id='4BC1677A44'><select id='4BC1677A44'><dt id='4BC1677A44'><span id='4BC1677A44'></span></dt></select></label></b><u id='4BC1677A44'></u>
          <i id='4BC1677A44'><strike id='4BC1677A44'><tt id='4BC1677A44'><pre id='4BC1677A44'></pre></tt></strike></i>

          Home / explore / focus

          focus


          focus

          author:focus    Page View:88

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In